Scientific and Medical Presentations

ASGCT 2020 Preclinical Pompe Data Update

May 14, 2020

ASGCT 2020 Fabry & Cystinosis Data Update

May 13, 2020

By proceeding further, you acknowledge and agree that your access to information contained in the “Medical and Scientific Conferences Presentations” section of the AVROBIO website:

  • is provided for informational purposes for use by the investor community only; and
  • may include information about investigational therapies that have not been approved by the applicable regulatory authorities as safe and effective.

In addition, the scientific or medical presentations included in the “Medical and Scientific Conferences Presentations” section of the AVROBIO website may contain forward-looking statements, which are generally statements that are not historical facts. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including those risks and uncertainties that are described in the Risk Factors section of AVROBIO’s most recent annual or quarterly report and in other reports AVROBIO has filed with the Securities and Exchange Commission (SEC) available at the SEC’s Internet (www.sec.gov). You should not place undue reliance on these statements or the scientific data presented. Forward-looking statements speak only as of the date of each presentation. Except as required by law, AVROBIO does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.